VCYT NASDAQ
Veracyte, Inc.
1W: +10.1%
1M: +6.1%
3M: -13.4%
YTD: +13.7%
1Y: +35.2%
3Y: +131.8%
5Y: +6.8%
$50.81
+2.61 (+5.41%)
Weekly Expected Move ±6.8%
$41
$45
$48
$51
$54
Credit Risk of going bust: lower than 72% of companies Debt: 1.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.07 (down 99.9%), Veracyte, Inc. would be worth roughly what it owes.
Total debt $40.1M against a stock market value of $3.87B.
Distance to default 8.00 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $20.1M (short-term plus half of long-term), stock volatility 64.2%; Altman Z'' 16.92. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.07 (down 99.9%), Veracyte, Inc. would be worth roughly what it owes.
Total debt $40.1M against a stock market value of $3.87B.
Distance to default 8.00 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $20.1M (short-term plus half of long-term), stock volatility 64.2%; Altman Z'' 16.92. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$3.9B
52W Range29.455-60.91
Volume748,098
Avg Volume1,348,271
Beta1.95
Dividend—
Analyst Ratings
Company Info
CEOMarc Stapley
Employees755
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2013-10-29
Websiteveracyte.com
6000 Shoreline Court
South San Francisco, CA 94080
US
South San Francisco, CA 94080
US
650 243 6300
About Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Latest News
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Gibbs Wealth Management Acquires New Holdings in Veracyte, Inc. $VCYT
Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report?
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Veracyte (NASDAQ:VCYT) Stock Price Breaks Below 200 Day Moving Average – Should You Sell?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Bhanji Muna | S-Sale | 1,864 | $43.70 | 2026-10-19 |
| Leite John | S-Sale | 4,015 | $40.00 | 2026-09-21 |
| Holstein Jens | S-Sale | 5,000 | $40.95 | 2026-09-14 |
| Febbo Phillip G. | S-Sale | 10,405 | $42.89 | 2026-09-04 |
| Febbo Phillip G. | S-Sale | 2,705 | $43.66 | 2026-09-04 |